We attempted to identify all associations previously reported from genome-wide or candidate analysis at a significance level P<5x10-8 for overall breast cancer, ER-negative or ER-positive breast cancer, in BRCA1 or BRCA2 carriers, or in meta-analyses of these categories. Where multiple studies reported associations in the same region, we used the first reported association unless later studies identified a variant that was clearly more strongly associated. We only included one SNP per 500kb interval, unless joint analysis provided clear evidence (P<5x10-8) of more than one independent signal. For the analysis of credible risk variants (CRVs), we restricted attention to regions where the most significant signal had a P-value<10-7 in Europeans (77 regions). To avoid complications with defining CRVs for secondary signals, we considered only the primary signal and defined CRVs as those whose P-value was within two orders of magnitude of the most significant P-value.